Posts by: Ana Pamplona, PhD

Ana Pamplona, PhD

Ana holds her PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL). She has worked in the T-cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, and has served as a scientific reviewer for the peer-reviewed journal Infection & Immunity.

December 4, 2014December 4, 2014

Crohn’s & Colitis Foundation Co-Funded Study Sheds Light On Immune System, Inflammation

Colon Cancer, Crohn's Disease, News

A new study on a potential regulation mechanism of autoimmunity and anti-tumor immunity entitled “CEACAM1 regulates TIM-3-mediated tolerance and exhaustion” was published in Nature by Yu-Hwa Huang, part of Dr. Richard ... Read more

December 1, 2014December 1, 2014

Healthy Gut Bacteria, Fat Content in Diet May Prevent Metabolic Syndrome

News

New insights into gut bacteria and their connection to metabolic syndrome have been uncovered by scientists. A study on Metabolic syndrome entitled “Intestinal Epithelial Cell Toll-like Receptor 5 Regulates the ... Read more

November 14, 2014November 14, 2014

E. Coli Bacteria Found in Gut Used as Long-Term Memory Device by MIT Scientists

News

A novel study on the use of engineered E. coli bacteria as a “genomic tape recorder” for cellular memories, entitled “Genomically encoded analog memory with precise in vivo DNA writing ... Read more

November 7, 2014November 7, 2014

GW Pharmaceuticals Announces Preliminary Topline Results from Phase 2a Ulcerative Colitis Trial

News, Ulcerative colitis

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics from its cannabinoid product platform and that commercialized the world’s first plant-derived cannabinoid prescription drug Sativex® ... Read more

October 28, 2014September 28, 2016

MS Drug Candidate May Also Treat Ulcerative Colitis

News, Ulcerative colitis

Receptos, Inc., a San Diego-based biotechnology company, announced promising new clinical data for its drug candidate RPC1063 for ulcerative colitis. The drug was first discovered and synthesized at The Scripps Research Institute (TSRI) by ... Read more

October 8, 2014October 8, 2014

Crohn’s Disease Research Could Benefit From discovery of Small Molecule Associated With Inflammatory Cell Death

IBD News, News

A new study, entitled “Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death” published in the journal Proceedings of the National Academy ... Read more

September 24, 2014September 24, 2014

Researchers Offer Groundbreaking Insights into IBD Genetics

IBD News, News

A recent review on inflammatory bowel disease (IBD) entitled “Advances in IBD Genetics” was published in Nature Reviews Gastroenterology & Hepatology by Johan Van Limbergen, M.D., FRCPCH, Ph.D., assistant professor and clinician ... Read more

September 9, 2014September 9, 2014

Long-term Use of Adalimumab Yields Promising Benefits For Ulcerative Colitis Patients

News, Ulcerative colitis

According to a recent study, prolonged treatment with Adalimumab, a TNF inhibiting anti-inflammatory drug, is beneficial for patients with moderately to severely active ulcerative colitis (UC). The study was conducted at the University ... Read more